1Green JR,Muller K,Jaeggi K A.Preclinical Pharmacology of CGP42446.a new,potent,heterocyclic bisphosphonate compound[J].J Bone Miner Res.1994,9(5):745-751.
2Coleman RE.Purohit OP.Black C,et al.Ibandronate:a well toierated new oral bisphosphonate for the treatment of bone metastases[J].Breast,1995,4(9):236.
3Jeal W,Barradell LB,Mctavish D.Alendronate:a review of its pharmacologocal properties and therapeutic efficacy in postmentopausal osteoporosis[J].Drugs,1997,53(3):415.
4Pecherstorfer M,Ludwig H,Schlosser K,et al.Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection[J].J Bone Miner Res,1996,14(5):587-593.
6Boisser S,Magnetto S,Frappart L,et al.Bisphosphonate inhibit prostate and breast carcinoma cell adhesion to ummineralized and mineralized bone extra cellular matrices[J].Cancer Res,1997,57(18):3890.
5Rosen C J,Kessenich CR.Conparative clinical pharnacology and therapeutic use of bisphosphonates in metabolic bone diseases[ J].Drug,1996,51 (4):537 ～ 551.
6Green JR,Muller K,Jaeggi K A.Pharmacology of CGP42446.a new,potent,heterocyclic bisphosphonate compound[ J ].J Bone Miner Res,1994,9 (5):745 ～ 751.
